Zusammenfassung
Transforming growth factor (TGF) beta is the central cytokine in fibrotic liver diseases. We analyzed whether hepatoprotective adiponectin directly interferes with TGF beta 1 signaling in primary human hepatocytes (PHH). Adiponectin induces the TGF beta decoy receptor BMP-and activin-membrane-bound inhibitor (BAMBI) in PHH. Overexpression of BAMBI in hepatoma cells impairs TGF beta-mediated ...
Zusammenfassung
Transforming growth factor (TGF) beta is the central cytokine in fibrotic liver diseases. We analyzed whether hepatoprotective adiponectin directly interferes with TGF beta 1 signaling in primary human hepatocytes (PHH). Adiponectin induces the TGF beta decoy receptor BMP-and activin-membrane-bound inhibitor (BAMBI) in PHH. Overexpression of BAMBI in hepatoma cells impairs TGF beta-mediated phosphorylation of SMAD2 and induction of connective tissue growth factor. BAMBI is lower in human fatty liver with a higher susceptibility to liver fibrosis and negatively correlates with BMI of the donors. Hepatic BAMBI is reduced in rodent models of liver inflammation and fibrosis. In summary, the current data show that hepatoprotective effects of adiponectin include induction of BAMBI which is reduced in human fatty liver and rodent models of metabolic liver injury. (C) 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
Altmetric